The Medical Laboratory Science Council of Nigeria (MLSCN)has approved a new drug for treatment of malaria with a dose capable of eliminating the parasite.
The Acting Registrar and Chief Executive Officer, Mr Erhabor Tosan disclosed this at the closing ceremony of the Second National Conference organised by Young Medical Laboratory Scientists Forum in Abuja on Monday, with theme: “Antimicrobial Resistance; a global health challenge in the fight for sustainable health system”.
Tosan said that the new malaria drug was first approved by U. S. regulators.
“This development is gratifying because it will give hope to the millions of people in Sub-Sahara Africa currently battling with the debilitating effects of reccurring malaria disease. The drug is said to be effective in eliminating the parasite with a single dose, and sooner than later be licensed for the treatment of malaria in vulnerable societies such as ours” he said.
The acting registrar expressed hope that the summit would produce meaningful frameworks for countering menace of Antimicrobial Resistance (AMR) which was reaching alarming level in the country.
AMR occurs when micro organism such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections ineffective.
He said that rampaging microorganisms such as bacteria, viruses and others have become impervious to the regular and conventional agents such as antibiotics, antivirals or anti malaria available to the citizens.
“When considered in relation to the current state of our health care system, it becomes easier to appreciate the magnitude of challenges facing us as health care professionals. YMLSF deserves commendation for bringing this subject matter to the front banner and we must appreciate the forum’s consciousness and proactiveness towards prevailing health issues in the country”
According to him, MLSCN as a regulatory body for medical laboratory services will always stand with the forum and other stakeholders in pursuit of excellence in the profession.